All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The Lymphoma Hub was pleased to speak to the president of EBMT, Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, How does CAR T-cell therapy compare with allogenic stem cell transplant (allo-SCT) for treating relapsed or refractory large B cell lymphoma (LBCL)?
How does CAR T-cell therapy compare with allo-SCT for treating R/R LBCL?
Sureda begins by highlighting the role of allo-SCT as the standard of care for patients with relapsed or refractory LBCL, with this being a stand-alone treatment option when other therapies have not been successful. Sureda then describes how the ZUMA-1, JULIET, and TRANSCEND trials have provided pivotal data to further elucidate how these therapies vary across lymphoma subtypes. Sureda explains that long-term follow-up studies are vital in tracking the success rate of CAR T-cell therapies and how they could now be an alternative to allo-SCT. However, though data seen in long-term studies of CAR T-cell therapy show higher remission rates and reduced active disease post-treatment, relapse rates are still higher in patients treated with CAR T-cell therapy than allo-SCT. Sureda uses data from various studies to compare CAR T-cell therapy and allo-SCT in varying subtypes of lymphoma, describing how individual patients would benefit from either treatment depending on their history.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox